Extensively Drug-Resistant Tuberculosis

"Extensively Drug-Resistant Tuberculosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.

Descriptor ID	D054908
MeSH Number(s)	C01.252.410.040.552.846.775.500
Concept/Terms	Extensively Drug-Resistant Tuberculosis Extensively Drug-Resistant Tuberculosis Extensively Drug Resistant Tuberculosis Extremely Drug-Resistant Tuberculosis Drug-Resistant Tuberculoses, Extremely Drug-Resistant Tuberculosis, Extremely Extremely Drug Resistant Tuberculosis Extremely Drug-Resistant Tuberculoses Tuberculoses, Extremely Drug-Resistant Tuberculosis, Extremely Drug-Resistant Tuberculosis, Extremely Drug Resistant XDR-TB Tuberculosis, Extensively Drug-Resistant Drug-Resistant Tuberculoses, Extensively Drug-Resistant Tuberculosis, Extensively Extensively Drug-Resistant Tuberculoses Tuberculoses, Extensively Drug-Resistant Tuberculosis, Extensively Drug Resistant

Below are MeSH descriptors whose meaning is more general than "Extensively Drug-Resistant Tuberculosis".

Diseases [C]
Bacterial Infections and Mycoses [C01]
Bacterial Infections [C01.252]
Gram-Positive Bacterial Infections [C01.252.410]
Actinomycetales Infections [C01.252.410.040]
Mycobacterium Infections [C01.252.410.040.552]
Tuberculosis [C01.252.410.040.552.846]
Tuberculosis, Multidrug-Resistant [C01.252.410.040.552.846.775]
Extensively Drug-Resistant Tuberculosis [C01.252.410.040.552.846.775.500]

Below are MeSH descriptors whose meaning is related to "Extensively Drug-Resistant Tuberculosis".

Below are MeSH descriptors whose meaning is more specific than "Extensively Drug-Resistant Tuberculosis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Extensively Drug-Resistant Tuberculosis" by people in this website by year, and whether "Extensively Drug-Resistant Tuberculosis" was a major or minor topic of these publications.

Bar chart showing 20 publications over 9 distinct years, with a maximum of 5 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	1	0	1
2011	2	0	2
2014	3	1	4
2015	1	1	2
2016	2	0	2
2017	2	0	2
2018	5	0	5
2019	0	1	1
2021	1	0	1

Below are the most recent publications written about "Extensively Drug-Resistant Tuberculosis" by people in Profiles.

Roelens M, Battista Migliori G, Rozanova L, Estill J, Campbell JR, Cegielski JP, Tiberi S, Palmero D, Fox GJ, Guglielmetti L, Sotgiu G, Brust JCM, Bang D, Lienhardt C, Lange C, Menzies D, Keiser O, Raviglione M. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2021 09 15; 204(6):713-722.

View in: PubMed
Kranzer K, Kalsdorf B, Heyckendorf J, Andres S, Merker M, Hofmann-Thiel S, Bloemberg GV, Hoffmann H, Niemann S, Lange C, Maurer FP. New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared? Am J Respir Crit Care Med. 2019 08 15; 200(4):514-515.

View in: PubMed
Lange C, Chesov D, Furin J, Udwadia Z, Dheda K. Revising the definition of extensively drug-resistant tuberculosis. Lancet Respir Med. 2018 12; 6(12):893-895.

View in: PubMed
Dheda K, Gumbo T, Lange C, Horsburgh CR, Furin J. Pan-tuberculosis regimens: an argument against. Lancet Respir Med. 2018 04; 6(4):240-242.

View in: PubMed
Heyckendorf J, van Leth F, Kalsdorf B, Olaru ID, Günther G, Salzer HJF, Terhalle E, Rolling T, Glattki G, Müller M, Schuhmann M, Avsar K, Lange C. Relapse-free cure from multidrug-resistant tuberculosis in Germany. Eur Respir J. 2018 02; 51(2).

View in: PubMed
Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M. What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2018 02; 62(2).

View in: PubMed
Ikram AI, Satti ML, Lalani FK, Zaman G, Gardezi AH, Ahmed P. Evaluation of Nitrate Reductase Assay for Early Detection of Multi and Extensively Drug Resistance Tuberculosis in our Setup. J Coll Physicians Surg Pak. 2018 Jan; 28(1):22-25.

View in: PubMed
Abadie ME, Strich JR, Kim T, Xie YL, Fennelly KP, Olivier KN, Waldman M, Arora K, Holland SM, Chen RY. Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis. Eur Respir J. 2017 12; 50(6).

View in: PubMed
Chesov D, Ciobanu N, Lange C, Schön T, Heyckendorf J, Crudu V. Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation. Eur Respir J. 2017 10; 50(4).

View in: PubMed
Olaru ID, Lange C, Indra A, Meidlinger L, Huhulescu S, Rumetshofer R. High Rates of Treatment Success in Pulmonary Multidrug-Resistant Tuberculosis by Individually Tailored Treatment Regimens. Ann Am Thorac Soc. 2016 08; 13(8):1271-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals